SCHEMBL6493687

SCHEMBL6493687

Cc1ccc(C(=O)O)cc1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
RXRA P19793 2/20 0.55
LDHA P00338 3/20 0.51
LDHB P07195 3/20 0.51
LMNA P02545 1/20 0.49
TAS2R14 Q9NYV8 1/20 0.48
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
PTPN1 P18031 2/20 0.45
PTPN2 P17706 1/20 0.45
PTPN6 P29350 1/20 0.45
SRD5A2 P31213 1/20 0.45
PLA2G10 O15496 1/20 0.44
PLA2G2A P14555 1/20 0.44
BCL2 P10415 1/20 0.44
BCL2L1 Q07817 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11143781 0.88 SRD5A2 (0.60) TSHRRXRARXRBRXRGALDH1A1
SCHEMBL27561164 0.87 ALDH1A1 (0.59) TSHRRXRARXRBALDH1A1MRGPRX4
SCHEMBL27510579 0.86 TSHR (0.56) TSHRRXRALDHALDHBLMNA
SCHEMBL14312211 0.85 DAO (0.47) TSHRTAS2R14ALDH1A1MRGPRX4
SCHEMBL12117445 0.84 ALDH1A1 (0.49) RXRALDHALDHBLMNAALDH1A1
SCHEMBL31307947 0.84 TSHR (0.61) TSHRLMNAPTPN1PTPN2PTPN6
SCHEMBL11152749 0.83 RXRA (0.49) TSHRRXRALMNAALDH1A1MRGPRX4
SCHEMBL27986872 0.82 TSHR (0.69) TSHRRXRALMNATAS2R14RXRB
SCHEMBL6772376 0.82 TSHR (0.69) TSHRLMNAPTPN1PTPN2PTPN6
SCHEMBL6943754 0.82 PTPN1 (0.56) RXRALDHALDHBLMNAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-6919335-B2 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection BRISTOL-MYERS SQUIBB CO. (US) 2005-07-19 US disclosed
CN-1206212-C Tri-substd. phenyl derivs. and analogues ASTRAZENECA AB (SE) 2005-06-15 CN disclosed
CN-1402703-A Tri-substd. phenyl derivs. and analogues ASTRAZENECA AB (SE) 2003-03-12 CN disclosed
EP-1276739-A2 HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME Bristol-Myers Squibb Company (US) 2003-01-22 EP disclosed
US-20020040022-A1 Heterocycles that are inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY 2002-04-04 US disclosed
WO-2001081340-A2 HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040022-A1 Heterocycles that are inhibitors of IMPDH enzyme XDH, IMPDH1, IMPDH2 TSHR 3496/4885RXRA 2438/4885LDHA 1820/4885
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 TSHR 3928/4885RXRA 647/4885LDHA 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.